DEA Places Seizure Treatment Drug Into Schedule V

May 31, 2022 |Other U.S.

The Drug Enforcement Administration is placing the newly approved drug ganaxolone in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective June 1, ganaxolone, which was granted approval by the FDA in March, is subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until July 1.